<p>BayBridge Capital Group LLC 在第三季度收购了强生（NYSE:JNJ - 免费报告）股票的新头寸，根据其最近向证券交易委员会的备案。该基金收购了 6203 股公司股票，价值约 115 万美元。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<ul>
<li>降息使这三只收益 ETF 比以往更具吸引力</li>
</ul>
<p>其他几家对冲基金最近也对 JNJ 的头寸进行了调整。Clark Asset Management LLC 在第二季度将其在强生的股份增加了 51.6%。Clark Asset Management LLC 现在拥有 8884 股公司股票，价值 135.7 万美元，此前在该期间又购买了 3025 股。北卡罗来纳州财政部长在第二季度将其在强生的持股增加了 8.3%。北卡罗来纳州财政部长现在拥有 1234945 股公司股票，价值 188,638,000 美元，此前在上个季度又收购了 94957 股。Avanza Fonder AB 在第二季度将其在强生的头寸提高了 2.9%。Avanza Fonder AB 现在拥有 234647 股公司股票，价值 35842000 美元，此前在该期间又收购了 6566 股。Talbot Financial LLC 在第三季度将其在强生的持股提高了 4.6%。Talbot Financial LLC 现在拥有 138424 股公司股票，价值 25667000 美元，此前在上个季度又购买了 6143 股。最后，Winnow Wealth LLC 在第二季度收购了强生的新股份，价值约 295,000 美元。69.55% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师评级变动</h2>
<p>几家研究公司最近对 JNJ 发表了评论。摩根士丹利将强生的目标价从 190.00 美元上调至 197.00 美元，并在 12 月 12 日的报告中给予该股票 “持平” 评级。巴克莱将强生的目标价从 176.00 美元上调至 197.00 美元，并在 12 月 2 日的研究报告中给予该公司 “持平” 评级。富国银行将强生的目标价从 212.00 美元上调至 230.00 美元，并在 12 月 12 日的报告中给予该公司 “超配” 评级。花旗将强生的目标价从 215.00 美元上调至 232.00 美元，并在 12 月 11 日的研究报告中给予该股票 “买入” 评级。最后，BMO 资本市场在 12 月 11 日的研究报告中重申了对强生股票的 “跑赢大盘” 评级。四位投资分析师对该股票给予了强烈买入评级，十四位给予了买入评级，九位给予了持有评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，平均目标价为 210.25 美元。</p>
<ul>
<li>辉瑞加大对减肥药的投资</li>
</ul>
<p><strong>查看我们关于 JNJ 的最新研究报告</strong></p>
<h2>强生的价格表现</h2>
<p>强生（NYSE:JNJ）股票在周五开盘时为 208.01 美元。该公司的 50 日简单移动平均为 199.39 美元，200 日简单移动平均为 180.50 美元。强生的 52 周低点为 140.68 美元，52 周高点为 215.18 美元。该公司的市值为 5011.4 亿美元，市盈率为 20.08，市盈增长比率为 2.25，贝塔值为 0.36。该公司的速动比率为 0.80，流动比率为 1.07，债务与股本比率为 0.50。</p>
<ul>
<li>5 只医疗保健股票值得关注，因为行业轮动正在全面展开</li>
</ul>
<p>强生（NYSE:JNJ - 获取免费报告）最近于 8 月 30 日发布了季度财报。该公司报告季度每股收益为 2.26 美元。强生的净利润率为 27.26%，股本回报率为 32.73%。该公司在该季度的收入为 240.2 亿美元。股票研究分析师预测，强生在当前年度将发布 10.58 美元的每股收益。</p>
<h2>强生的股息公告</h2>
<p>该公司最近还宣布了季度股息，已于 12 月 9 日支付。11 月 25 日的股东获得了 1.30 美元的股息。该股息的除息日期为 11 月 25 日。这代表着每年 5.20 美元的股息和 2.5% 的股息收益率。强生的股息支付比率目前为 50.19%。</p>
<h2>关于强生</h2>
<p>（免费报告）</p>
<p>强生是一家总部位于新泽西州新布伦瑞克的跨国医疗保健公司，开发、制造和销售广泛的产品，涵盖制药、医疗设备和以前的消费健康产品。该公司由约翰逊家族于 1886 年创立，已发展成为一个在全球多个国家开展业务和销售的全球医疗保健组织。</p>
<p>该公司的制药业务主要在其扬森研究与开发组织下进行，专注于免疫学、传染病、肿瘤学和神经科学等治疗领域的处方药。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过强生</li>
<li>在 1 月 1 日之前将 1000 美元投入这只股票 [不是 NVDA]</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>华盛顿为战争做准备</li>
<li>奇怪的水晶金属表现优于硅，最高可达 100 倍</li>
<li>来自奇怪的新 “AI 燃料” 的 33000% 繁荣？</li>
</ul>
<p><strong>想看看其他对冲基金持有的 JNJ 吗？</strong> 访问 HoldingsChannel.com 获取强生（NYSE:JNJ - 免费报告）的最新 13F 备案和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒是由叙述科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在强生吗？</h2>
<p>在考虑强生之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
<p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>BayBridge Capital Group LLC 在第三季度收购了 6,203 股强生，价值 1,150,000 美元。几家对冲基金调整了在 JNJ 的持仓。分析师对 JNJ 给出了 “适度买入” 的共识评级，平均目标价为 210.25 美元。强生的股票开盘价为 208.01 美元，市值为 5,011.4 亿美元。该公司宣布季度股息为 1.30 美元，收益率为 2.5%</p>

<p>BayBridge Capital Group LLC acquired a new position in shares of Johnson &amp; Johnson (NYSE:JNJ - Free Report) in the 3rd quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The fund acquired 6,203 shares of the company's stock, valued at approximately $1,150,000.</p>
<div class="lb-trans"><p>BayBridge Capital Group LLC 在第三季度收购了强生（NYSE:JNJ - 免费报告）股票的新头寸，根据其最近向证券交易委员会的备案。该基金收购了 6203 股公司股票，价值约 115 万美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><ul>
<li>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</li>
</ul>
<div class="lb-trans"><ul>
<li>降息使这三只收益 ETF 比以往更具吸引力</li>
</ul>
</div><p>Several other hedge funds have also recently made changes to their positions in JNJ. Clark Asset Management LLC raised its stake in shares of Johnson &amp; Johnson by 51.6% during the 2nd quarter. Clark Asset Management LLC now owns 8,884 shares of the company's stock worth $1,357,000 after buying an additional 3,025 shares during the period. Treasurer of the State of North Carolina increased its holdings in Johnson &amp; Johnson by 8.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company's stock worth $188,638,000 after acquiring an additional 94,957 shares in the last quarter. Avanza Fonder AB raised its position in Johnson &amp; Johnson by 2.9% during the second quarter. Avanza Fonder AB now owns 234,647 shares of the company's stock worth $35,842,000 after acquiring an additional 6,566 shares during the period. Talbot Financial LLC lifted its holdings in Johnson &amp; Johnson by 4.6% during the third quarter. Talbot Financial LLC now owns 138,424 shares of the company's stock valued at $25,667,000 after purchasing an additional 6,143 shares in the last quarter. Finally, Winnow Wealth LLC acquired a new stake in shares of Johnson &amp; Johnson in the second quarter valued at about $295,000. 69.55% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也对 JNJ 的头寸进行了调整。Clark Asset Management LLC 在第二季度将其在强生的股份增加了 51.6%。Clark Asset Management LLC 现在拥有 8884 股公司股票，价值 135.7 万美元，此前在该期间又购买了 3025 股。北卡罗来纳州财政部长在第二季度将其在强生的持股增加了 8.3%。北卡罗来纳州财政部长现在拥有 1234945 股公司股票，价值 188,638,000 美元，此前在上个季度又收购了 94957 股。Avanza Fonder AB 在第二季度将其在强生的头寸提高了 2.9%。Avanza Fonder AB 现在拥有 234647 股公司股票，价值 35842000 美元，此前在该期间又收购了 6566 股。Talbot Financial LLC 在第三季度将其在强生的持股提高了 4.6%。Talbot Financial LLC 现在拥有 138424 股公司股票，价值 25667000 美元，此前在上个季度又购买了 6143 股。最后，Winnow Wealth LLC 在第二季度收购了强生的新股份，价值约 295,000 美元。69.55% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several research firms have recently commented on JNJ. Morgan Stanley lifted their price target on Johnson &amp; Johnson from $190.00 to $197.00 and gave the stock an &#34;equal weight&#34; rating in a report on Friday, December 12th. Barclays increased their price target on shares of Johnson &amp; Johnson from $176.00 to $197.00 and gave the company an &#34;equal weight&#34; rating in a research note on Tuesday, December 2nd. Wells Fargo &amp; Company upped their price objective on Johnson &amp; Johnson from $212.00 to $230.00 and gave the company an &#34;overweight&#34; rating in a report on Friday, December 12th. Citigroup increased their price objective on Johnson &amp; Johnson from $215.00 to $232.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, December 11th. Finally, BMO Capital Markets restated an &#34;outperform&#34; rating on shares of Johnson &amp; Johnson in a research report on Thursday, December 11th. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $210.25.</p>
<div class="lb-trans"><p>几家研究公司最近对 JNJ 发表了评论。摩根士丹利将强生的目标价从 190.00 美元上调至 197.00 美元，并在 12 月 12 日的报告中给予该股票 “持平” 评级。巴克莱将强生的目标价从 176.00 美元上调至 197.00 美元，并在 12 月 2 日的研究报告中给予该公司 “持平” 评级。富国银行将强生的目标价从 212.00 美元上调至 230.00 美元，并在 12 月 12 日的报告中给予该公司 “超配” 评级。花旗将强生的目标价从 215.00 美元上调至 232.00 美元，并在 12 月 11 日的研究报告中给予该股票 “买入” 评级。最后，BMO 资本市场在 12 月 11 日的研究报告中重申了对强生股票的 “跑赢大盘” 评级。四位投资分析师对该股票给予了强烈买入评级，十四位给予了买入评级，九位给予了持有评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，平均目标价为 210.25 美元。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞加大对减肥药的投资</li>
</ul>
</div><p><strong>View Our Latest Research Report on JNJ</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 JNJ 的最新研究报告</strong></p>
</div><h2>Johnson &amp; Johnson Price Performance</h2>
<div class="lb-trans"><h2>强生的价格表现</h2>
</div><p>Shares of NYSE:JNJ opened at $208.01 on Friday. The business has a fifty day simple moving average of $199.39 and a 200-day simple moving average of $180.50. Johnson &amp; Johnson has a 52 week low of $140.68 and a 52 week high of $215.18. The company has a market cap of $501.14 billion, a P/E ratio of 20.08, a P/E/G ratio of 2.25 and a beta of 0.36. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ）股票在周五开盘时为 208.01 美元。该公司的 50 日简单移动平均为 199.39 美元，200 日简单移动平均为 180.50 美元。强生的 52 周低点为 140.68 美元，52 周高点为 215.18 美元。该公司的市值为 5011.4 亿美元，市盈率为 20.08，市盈增长比率为 2.25，贝塔值为 0.36。该公司的速动比率为 0.80，流动比率为 1.07，债务与股本比率为 0.50。</p>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只医疗保健股票值得关注，因为行业轮动正在全面展开</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson &amp; Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion during the quarter. Equities research analysts forecast that Johnson &amp; Johnson will post 10.58 EPS for the current year.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ - 获取免费报告）最近于 8 月 30 日发布了季度财报。该公司报告季度每股收益为 2.26 美元。强生的净利润率为 27.26%，股本回报率为 32.73%。该公司在该季度的收入为 240.2 亿美元。股票研究分析师预测，强生在当前年度将发布 10.58 美元的每股收益。</p>
</div><h2>Johnson &amp; Johnson Dividend Announcement</h2>
<div class="lb-trans"><h2>强生的股息公告</h2>
</div><p>The business also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were given a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. Johnson &amp; Johnson's dividend payout ratio is presently 50.19%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度股息，已于 12 月 9 日支付。11 月 25 日的股东获得了 1.30 美元的股息。该股息的除息日期为 11 月 25 日。这代表着每年 5.20 美元的股息和 2.5% 的股息收益率。强生的股息支付比率目前为 50.19%。</p>
</div><h2>About Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>关于强生</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.</p>
<div class="lb-trans"><p>强生是一家总部位于新泽西州新布伦瑞克的跨国医疗保健公司，开发、制造和销售广泛的产品，涵盖制药、医疗设备和以前的消费健康产品。该公司由约翰逊家族于 1886 年创立，已发展成为一个在全球多个国家开展业务和销售的全球医疗保健组织。</p>
</div><p>The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.</p>
<div class="lb-trans"><p>该公司的制药业务主要在其扬森研究与开发组织下进行，专注于免疫学、传染病、肿瘤学和神经科学等治疗领域的处方药。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Washington prepares for war</li>
<li>Strange Crystal Metal Outperforms Silicon Up to 100X</li>
<li>33,000% boom from weird new “AI Fuel?”</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过强生</li>
<li>在 1 月 1 日之前将 1000 美元投入这只股票 [不是 NVDA]</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
<li>华盛顿为战争做准备</li>
<li>奇怪的水晶金属表现优于硅，最高可达 100 倍</li>
<li>来自奇怪的新 “AI 燃料” 的 33000% 繁荣？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 JNJ 吗？</strong> 访问 HoldingsChannel.com 获取强生（NYSE:JNJ - 免费报告）的最新 13F 备案和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒是由叙述科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑强生之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

BayBridge Capital Group LLC 购入了 6,203 股强生公司股票$JNJ